文献速递神经肿瘤

泊沙康唑治疗胶质母细胞瘤的神经药理学研究:0期临床试验方案

Neuropharmacological Study of Posaconazole for Glioblastoma: A Phase 0 Clinical Trial Protocol.
PubMed 文献 · Neurosurgery · 2022-07-25

该0期试验为开放标签、非随机、平行组设计,纳入胶质母细胞瘤患者,干预组5例接受泊沙康唑,对照组5例不接受,随后行肿瘤切除并放置微透析导管,检测透析液、血浆和肿瘤样本中乳酸和丙酮酸浓度,评估泊沙康唑的脑肿瘤穿透性、神经药代动力学特征及其对肿瘤细胞代谢的机制效应。

要点

  • 泊沙康唑干预组5例与对照组5例,比较脑组织药物浓度与代谢物变化。
  • 主要预期结局包括强化区泊沙康唑浓度高于非强化区、乳酸/丙酮酸与药物浓度负相关、HK2活性降低。
  • 试验成功将支持进入后期试验,任何肿瘤穿透伴糖酵解效应均需进一步深入分析。

核心结论

  • 试验成功将支持进入后期试验的决定;泊沙康唑任何程度的肿瘤穿透并伴随糖酵解效应均需进一步深入分析。

研究设计与样本

  • 开放标签、非随机、平行组0期临床试验方案,纳入胶质母细胞瘤患者,干预组接受泊沙康唑(n=5),对照组不接受泊沙康唑(n=5),随后行肿瘤切除并放置微透析导管。

主要发现

  • 预期结局包括:强化区泊沙康唑浓度高于非强化区;治疗患者透析液中乳酸/丙酮酸与泊沙康唑浓度随时间呈负相关;泊沙康唑处理的肿瘤样本中HK2活性降低。

关键数值与推荐

  • 泊沙康唑神经药代动力学基于脑间质中泊沙康唑浓度的浓度-时间曲线和0至24小时曲线下面积确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common malignant primary brain tumor with a universally poor prognosis. GBMs express elevated levels of hexokinase 2 (HK2), catalyzing the critical step in glycolysis and influencing several oncogenic pathways. Previous preclinical work has suggested a role for repurposed posaconazole (PCZ) in downregulating HK2 activity, reducing lactate and pyruvate production, interfering with tumor cell metabolism, and increasing mouse survival. OBJECTIVE: To establish brain tumor penetrance, neuropharmacokinetic profile, and mechanistic effect on tumor cell metabolism of PCZ in adults with GBM. METHODS: This is an open label, nonrandomized, parallel arm trial involving patients with GBM. Cohorts will receive PCZ (intervention, n = 5) or will not receive PCZ (control, n = 5), followed by tumor resection and microdialysis catheter placement. Dialysate, plasma, and tumor samples will be analyzed for lactate and pyruvate concentrations. Tumor samples will also be assessed for PCZ concentration, HK2 expression, angiogenesis, and apoptosis. PCZ's neuropharmacokinetics will be determined based on the concentration vs time profile and area under the curve 0 to 24 hours of PCZ concentration in the brain interstitium. EXPECTED OUTCOMES: (1) Increased PCZ concentration in contrast-enhancing brain regions compared with nonenhancing regions; (2) inverse correlation between lactate/pyruvate and PCZ concentrations in dialysate samples from treated patients, over time; and (3) decreased HK2 activity in PCZ-treated tumor samples. DISCUSSION: A successful trial will support the decision to proceed to advanced phase trials. Any tumor penetration by PCZ, with concomitant effect on glycolysis, warrants further in-depth analysis, as therapeutic options for these deadly tumors are currently limited.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Bhanja D, Neighbors J, Connor J, et al. Neuropharmacological Study of Posaconazole for Glioblastoma: A Phase 0 Clinical Trial Protocol. Neurosurgery. 2022. PMID: 35861778. doi:10.1227/neu.0000000000002071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。